Please assess the completion status of the following clinical trial:

Trial Title: Human Fibrinogen - Pharmacokinetics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 6 years~* Documented congenital fibrinogen deficiency: fibrinogen deficiency manifested as afibrinogenemia with plasma fibrinogen activity and antigen at screening undetectable (i.e. \< 20 mg/dL)~* Informed consent signed by subject or legal guardian~Exclusion Criteria:~* Presence or history of hypersensitivity to Human Fibrinogen Concentrate or human plasma proteins,~* Presence or history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis~* Acute bleeding~* History of esophageal varicose bleeding~* End stage liver disease (i.e. Child-Pugh score B or C)~* Planned major surgery with a need for blood transfusion during the PK blood sampling period~* Polytrauma within 1 year prior to enrollment

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Human Fibrinogen Concentrate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).